Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Trials
|
December 7, 2023
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial
Robert K Mahar, Anna McGlothlin, Michael Dymock, et al.
BMJ Open Respiratory Research
|
August 16, 2023
Randomised controlled trial of perinatal vitamin D supplementation to prevent early-onset acute respiratory infections among Australian First Nations children: the 'D-Kids' study protocol
Michael J Binks, Amy S Bleakley, Susan J Pizzutto, et al.
BMJ Open
|
May 26, 2020
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
Victor M Oguoma, Nicole Wilson, Kim Mulholland, et al.
The Journal of Infection
|
May 25, 2025
Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines
Gladymar Pérez Chacón, Sonia McAlister, James Totterdell, et al.
Plos Medicine
|
June 10, 2024
Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial
Gladymar Pérez Chacón, Marie J Estcourt, James Totterdell, et al.
Transplantation and Cellular Therapy
|
February 8, 2025
Co-designing a Novel Ordinal Endpoint for an Adaptive Platform Trial, BANDICOOT, in Pediatric Hematopoietic Stem Cell Transplant
Hannah Walker, Lorna McLeman, Deborah Meyran, et al.
The Lancet. Infectious Diseases
|
June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials
Amanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Journal of the Pediatric Infectious Diseases Society
|
December 15, 2025
Follow-up and Outcomes of Infants Perinatally-exposed to HIV in a Low-prevalence Setting: The Multicenter Children's HIV Exposure Study 2
Penelope A Bryant, Adam W Bartlett, Asha Bowen, et al.
Vaccine
|
November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study
Nusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
Plos Medicine
|
June 3, 2024
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules
Amanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Trials
|
December 7, 2023
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial
Robert K Mahar, Anna McGlothlin, Michael Dymock, et al.
BMJ Open Respiratory Research
|
August 16, 2023
Randomised controlled trial of perinatal vitamin D supplementation to prevent early-onset acute respiratory infections among Australian First Nations children: the 'D-Kids' study protocol
Michael J Binks, Amy S Bleakley, Susan J Pizzutto, et al.
BMJ Open
|
May 26, 2020
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
Victor M Oguoma, Nicole Wilson, Kim Mulholland, et al.
The Journal of Infection
|
May 25, 2025
Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines
Gladymar Pérez Chacón, Sonia McAlister, James Totterdell, et al.
Plos Medicine
|
June 10, 2024
Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial
Gladymar Pérez Chacón, Marie J Estcourt, James Totterdell, et al.
Transplantation and Cellular Therapy
|
February 8, 2025
Co-designing a Novel Ordinal Endpoint for an Adaptive Platform Trial, BANDICOOT, in Pediatric Hematopoietic Stem Cell Transplant
Hannah Walker, Lorna McLeman, Deborah Meyran, et al.
The Lancet. Infectious Diseases
|
June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials
Amanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Journal of the Pediatric Infectious Diseases Society
|
December 15, 2025
Follow-up and Outcomes of Infants Perinatally-exposed to HIV in a Low-prevalence Setting: The Multicenter Children's HIV Exposure Study 2
Penelope A Bryant, Adam W Bartlett, Asha Bowen, et al.
Vaccine
|
November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study
Nusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
Plos Medicine
|
June 3, 2024
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules
Amanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Page
of 8